Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Accounts Payables: 2018-2025

  • Dr Reddys Laboratories' Accounts Payables rose 12.40% to $417.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $417.0 million, marking a year-over-year increase of 12.40%. This contributed to the annual value of $417.0 million for FY2025, which is 12.40% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Accounts Payables stood at $417.0 million for Q1 2025, which was up 12.40% from $371.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' 5-year Accounts Payables high stood at $417.0 million for Q1 2025, and its period low was $322.0 million during Q1 2023.
  • In the last 3 years, Dr Reddys Laboratories' Accounts Payables had a median value of $371.0 million in 2024 and averaged $370.0 million.
  • As far as peak fluctuations go, Dr Reddys Laboratories' Accounts Payables surged by 47.06% in 2021, and later declined by 4.45% in 2023.
  • Over the past 5 years, Dr Reddys Laboratories' Accounts Payables (Quarterly) stood at $325.0 million in 2021, then increased by 3.69% to $337.0 million in 2022, then decreased by 4.45% to $322.0 million in 2023, then climbed by 15.22% to $371.0 million in 2024, then climbed by 12.40% to $417.0 million in 2025.
  • Its Accounts Payables was $417.0 million in Q1 2025, compared to $371.0 million in Q1 2024 and $322.0 million in Q1 2023.